SCHEMBL20135726

SCHEMBL20135726

CC(C)(C)C1(c2ccc(C(=O)O)nc2)NC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 12/20 0.38
P4HA1 P13674 1/20 0.38
MIF P14174 1/20 0.38
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HIF1A Q16665 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
THPO P40225 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135463 0.80 B3GNT2 (0.36) ALDH1A1KMT2AMEN1LMNAMAPT
SCHEMBL20134886 0.80 MEN1 (0.50) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL20135719 0.75 TDP1 (0.37) KDM4EALDH1A1TDP1LMNAMAPT
SCHEMBL20135182 0.73 HCAR3 (0.41) P4HTMP4HA1MIFALDH1A1CYP1A2
SCHEMBL20134906 0.69 CA1 (0.37) ALDH1A1KMT2AMEN1LMNAMAPT
SCHEMBL20135320 0.63 CA1 (0.34) ALDH1A1KMT2AMEN1AKR1B1
SCHEMBL21063431 0.63 P4HTM (0.46) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL13731115 0.62 P4HTM (0.64) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3203433 0.62 P4HTM (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL21063532 0.62 P4HTM (0.44) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 P4HTM 857/4885P4HA1 840/4885MIF 25/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 P4HTM 868/4885P4HA1 801/4885MIF 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.